NASDAQ:EQ Equillium Q2 2023 Earnings Report $0.42 -0.01 (-1.40%) Closing price 04:00 PM EasternExtended Trading$0.43 +0.01 (+3.35%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Equillium EPS ResultsActual EPS-$0.10Consensus EPS -$0.19Beat/MissBeat by +$0.09One Year Ago EPSN/AEquillium Revenue ResultsActual Revenue$9.12 millionExpected Revenue$8.60 millionBeat/MissBeat by +$520.00 thousandYoY Revenue GrowthN/AEquillium Announcement DetailsQuarterQ2 2023Date8/9/2023TimeN/AConference Call DateWednesday, August 9, 2023Conference Call Time8:00AM ETUpcoming EarningsEquillium's Q1 2025 earnings is scheduled for Wednesday, August 6, 2025Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Equillium Earnings HeadlinesEquillium (NASDAQ:EQ) Trading Up 3.9% - Here's What HappenedJuly 16 at 3:15 AM | americanbankingnews.comInterleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightJuly 11, 2025 | finance.yahoo.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 18 at 2:00 AM | Brownstone Research (Ad)Equillium, Inc. (EQ) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.comEquillium expands equity incentive plan by 1.78 million sharesMay 24, 2025 | investing.comEquillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of ImmunologistsMay 6, 2025 | finance.yahoo.comSee More Equillium Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email. Email Address About EquilliumEquillium (NASDAQ:EQ) is a clinical‐stage biotechnology company focused on the discovery and development of novel immunomodulatory therapies for the treatment of severe autoimmune and inflammatory disorders. Founded in 2014 and headquartered in San Diego, California, Equillium applies its proprietary immunology platform to advance a pipeline of antibody‐based product candidates designed to modulate T cell activity and restore immune balance. The company’s lead candidate, itolizumab (EQ001), is a humanized anti‐CD6 monoclonal antibody originally licensed from Biocon and engineered to minimize immune response while targeting T cell activation. Itolizumab is being evaluated in pivotal trials for acute graft‐versus‐host disease following hematopoietic stem cell transplantation. Equillium’s second program, EQ002, is engineered to address chronic inflammatory conditions such as psoriasis and lupus by selectively inhibiting proinflammatory cytokines without broadly suppressing the immune system. Equillium conducts multinational clinical studies across North America, Europe and Asia, collaborating with academic medical centers and regulatory agencies to examine safety, efficacy and biomarker-driven patient selection. The company’s research and development facilities in the United States are complemented by manufacturing partnerships that support both preclinical and clinical stage production under Good Manufacturing Practice (GMP) standards. Under the leadership of President and Chief Executive Officer Roger Pomerantz and Chief Medical Officer Dr. Lavanya Ambati, Equillium has expanded its management team with seasoned professionals in immunology, clinical operations and regulatory affairs. The organization remains committed to translating scientific innovation into transformative therapies for patients suffering from life‐threatening immune‐mediated diseases.Written by Jeffrey Neal JohnsonView Equillium ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
